"T cells and cancer cells have a lot of interactive targeted molecules between them that interact, and the antibodies get in the way and either stop or stimulate those interactions. Having Bionovion allows us, downstream, to be first in making antibodies for some of these novel targets. The value of that will become apparent as we move the pipeline forward."
Stephen Isaacs, chairman, president and CEO of Aduro Biotech Inc., discussing the acquisition of Dutch biotech Bionovion Holding BV and integration of its antibody candidates with Aduro's immunotherapies

"Ocrelizumab is interesting in that it reduces the number of B cells, a white blood cell that we think is involved in inflammation. In progressive MS, we know that there are B cells that are compartmentalized within the nervous system and we think that they're playing a role in progression."
Bruce Bebo, executive vice president of research, National MS Society

"Lonsurf is currently our only product in the U.S., so for us to expand more into the international market, product life cycle management of Lonsurf such as expanding indications is important. New oncology products currently on Taiho's pipeline will follow Lonsurf and will be on the international market in the coming years."
Yukie Shibata, spokeswoman for Taiho Oncology Inc., on the FDA approval of Taiho's oral combination anticancer drug TAS-102 (trifluridine hydrochloride) for refractory metastatic colorectal cancer, which is marketed in Japan under the brand name Lonsurf